A retrospective analysis of GSE84010: Cell adhesion molecules might contribute to bevacizumab resistance in glioblastoma |
| |
| Affiliation: | 1. Department of Neurosurgery, Cleveland Clinic, Cleveland, OH, United States;2. Department of Neurosurgery, University of Texas Southwestern Medical Center, Dallas, TX, United States;1. Departments of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan;2. Radiology and Radiation Oncology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan;3. Pathology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan;4. Department of General Internal Medicine, JCHO Sendai Hospital, Sendai, Miyagi, Japan;1. Neurosurgery Department. Hospital Universitario y Politécnico La Fe, Valencia, Spain;2. Pathology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain;3. Brain Tumour Laboratory, Fundación Vithas, Grupo Hospitales Vithas, Madrid, Spain;4. Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain;5. Nanomedicine and Sensors Unit, Hospital Universitario y Politécnico La Fe, Universidad Politécnica de Valencia, Spain;1. Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy;2. Neurology Unit, Careggi University Hospital, Florence, Italy;3. IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy;1. Division of Neurosurgery, University of São Paulo Medical School, São Paulo, Brazil;2. Laboratory of Experimental Surgery, University of São Paulo Medical School, São Paulo, Brazil;3. Universidad El Bosque, Calle 134 Cra 9, Bogotá, Colombia;4. Neurointensive Care Unit, Sanatorio Pasteur. Intensive Care Unit, Hospital Carlos G. Malbran, Catamarca, Argentina;5. Hospital Samaritano, Americas Serviços Médicos, São Paulo, Brazil |
| |
| Abstract: | Bevacizumab (BEV) is an anti-angiogenesis antibody which has shown favorable therapeutic effects on some solid tumors. However, many clinical trials showed that BEV could only improve PFS instead of OS in glioblastoma (GBM) patients. However, some studies indicate that specific molecular subtypes of GBM could still benefit from combination treatment of BEV and Stupp protocol. Through the subgroup analysis of GSE84010 dataset, we found the neural and proneural subgroup can benefit from the administration of BEV in terms of OS, which is statistically significant. The further KEGG pathway enrichment analysis showed cell adhesion molecules (CAMs) pathway was enriched, and the expression of ITGAM has a predictive value for prognosis. These findings can provide some hints for future administration of BEV in newly diagnosed GBM patients. |
| |
| Keywords: | Bevacizumab Anti-angiogenesis Glioblastoma Subtype Cell adhesion molecules |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
